Review of duloxetine in the management of diabetic peripheral neuropathic pain

Vascular Health and Risk Management

Volumn 3, Issue 6, 2007, Pages 833-844

  Smith, Timothy ^a   Nicholson, Robert A ^b  

^a Mercy Health Research and Ryan Headache Center   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Central sensitization; Diabetic neuropathy; Duloxetine; Selective serotonin norepinephrine reuptake inhibitor (SNRI)

Indexed keywords

ALUMINUM; AMITRIPTYLINE; ANTIFUNGAL AGENT; CIMETIDINE; CIPROFLOXACIN; DESIPRAMINE; DULOXETINE; FAMOTIDINE; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MACROLIDE; MAGNESIUM HYDROXIDE; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; NORTRIPTYLINE; PAROXETINE; PHENOTHIAZINE DERIVATIVE; PLACEBO; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; THIONISOXETINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ALLODYNIA; ANALGESIC ACTIVITY; ANTICHOLINERGIC SYNDROME; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DIABETIC NEUROPATHY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FATIGUE; FOOD; FOOD DRUG INTERACTION; HUMAN; HYPOTENSION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROPATHIC PAIN; NEUROPROTECTION; NOCICEPTION; NONHUMAN; PAIN ASSESSMENT; PATIENT COMPLIANCE; PHARMACODYNAMICS; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

CLINICAL TRIALS AS TOPIC; DIABETIC NEUROPATHIES; DRUG INTERACTIONS; HUMANS; MOLECULAR STRUCTURE; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 38149071546     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Anderson N, Oren P, Ogura T, et al. 1996. Duloxetine enteric pellets. Official Gazette of the United States Patent and Trademark Office Patents, 1185:1954.
2. Bymaster F, Dreshfield-Ahmad L, Threlkeld P, et al. 2001. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors. Neuropsychopharmacology, 25:871-80.
3. DiVirgilio S, Gonzales C, Knadler M, et al. 2002. Effect of duloxetine (DU) on CYP1A2-mediated drug metabolism and the pharmacokinetics (PK) of theophylline (THEO). Clin Pharmacol Ther, 71:63.
4. Goldstein D, Lu Y, Detke MJ, et al. 2005. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain, 116:109-18.
5. Hoke A, Feasby T. Disorders of the peripheral nervous system. 2000. In Humes H. ed. Kelley's Textbook of Internal Medicine. Philadelphia: Lippincott Williams and Wilkins. p. 2980-1.
6. Iyengar S, Webster A, Hemrick-Luecke S, et al. 2004. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. JPET, 311:576-84.
7. Kuo F, Gillespie T, Kulanthaivel P, et al. 2004. Synthesis and biological activity of some known and putative duloxetine metabolites. Bioorg Med Chem Lett, 14:3481-6.
8. Lantz R, Gillespie T, Rash T, et al. 2003. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos, 31:1142-50.
9. Lynch M. 2001. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci, 26:30-6.
10. Raskin J, Pritchett YL, Wang F, et al. 2005. A double-blind, randomized mutlicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med, 6:346-56.
11. Raskin J, Smith TR, Wong K, et al. 2006. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med, 9:29-40.
12. Sathirakul K, Teng L, Yeo Y, et al. 2002. Impact of gastric pH and the presence of activated charcoal on the absorption of duloxetine. Int J Clin Pharmacol, 71:18.
13. Skinner M, Kuan H, Pan A, et at. 2003. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther, 73:170-7.
14. Skinner M, Weerakkody G. 2002. Duloxetine does not exacerbate the effects of alcohol on psychometric tests. Clin Pharmacol Ther, 71:53.
15. Eli Lilly and Company. 2007. Cymbalta (duloxetine) package insert [online]. Accessed March 1, 2007. URL: http://pi.lilly.com/us/ cym-balta-pi.pdf.
16. Wada R, Yagihashi S. 2005. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci, 1043:598-604.
17. Wernicke JF, Pritchett YL, D'Sousa DN, et al. 2006a. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology, 67:1411-20.
18. Wernicke JF, Raskin J, Rosen A, et al. 2006b. Duloxetine in long-term management of diabetic peripheral neuropathic pain: an open-label, 52 week extension of a randomized controlled clinical trial. Curr Ther Res Clin Exp, 67:283-304.
19. Wernicke JF, Wang F, Pritchett YL, et al. In press. An open-label 52 week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Medf.
20. Wong D, Byrnaster F. 2002. Dual serotonin and noradrenalin reuptake inhibitor class of anti-depressants: potential for greater efficacy or just hype? Prog Drug Res, 58:169-222.
21. Wong D, Bymaster F, Mayle D, et al. 1993. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology, 8:23-33.
22. Woolf C, Mannion R. 1999. Neuropathic pain: aetiology, symptoms, mechanisms and management. Lancet, 353:1959-64.
23. Yaksh T. 1985. Pharmacology of spinal adrenergic systems which modulate spinal nociceptive processing. Pharmacol Biochem Behav, 22:845-58.
24. Zhou M, Gebhart G. 1997. Biphasic modulation of spinal nociceptive transmission from the medullary raphe nuclei in the rat. J Neurophysiol, 78:746-58.